Jon W. Henry

Array ( [id] => 15898479 [patent_doc_number] => 20200148758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => THERAPEUTIC COMBINATIONS COMPRISING EOSINOPHIL-DEPLETING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/621532 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12222 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440747 [patent_doc_number] => 20180271916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Treatment of diseases and conditions caused by increased vascular permeability [patent_app_type] => utility [patent_app_number] => 15/990718 [patent_app_country] => US [patent_app_date] => 2018-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8500 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14583929 [patent_doc_number] => 20190219573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => BIOMARKER SIGNATURES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/990335 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990335 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901881 [patent_doc_number] => 20190040145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => ANTIBODY MOLECULE FOR HUMAN GM-CSF RECEPTOR ALPHA [patent_app_type] => utility [patent_app_number] => 15/980664 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657430 [patent_doc_number] => 20210054066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/331935 [patent_app_country] => US [patent_app_date] => 2018-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13246 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16331935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17513693 [patent_doc_number] => 11292823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-05 [patent_title] => Type I and type III interferon fusion molecules and methods for use thereof [patent_app_type] => utility [patent_app_number] => 16/604666 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 14334 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13493065 [patent_doc_number] => 20180298075 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => Interferon Analogs [patent_app_type] => utility [patent_app_number] => 15/950512 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16569186 [patent_doc_number] => 20210008192 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => MULTIPLE ANTIGEN PRESENTING SYSTEM (MAPS)-BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/498856 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498856 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311503 [patent_doc_number] => 20180207288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => METHOD FOR TREATING IFNALPHA RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 15/935344 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15935344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17859806 [patent_doc_number] => 11440951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Therapeutic antibodies to Marburg virus [patent_app_type] => utility [patent_app_number] => 16/491672 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 13580 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12889270 [patent_doc_number] => 20180188265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => DIAGNOSTIC BLOOD TEST FOR SARCOIDOSIS [patent_app_type] => utility [patent_app_number] => 15/903622 [patent_app_country] => US [patent_app_date] => 2018-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15903622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15145087 [patent_doc_number] => 20190351021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => IMMUNE-CELL TARGETED BISPECIFIC CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/475305 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605993 [patent_doc_number] => 10906985 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Targeted engineered interferon and uses thereof [patent_app_type] => utility [patent_app_number] => 16/483109 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 52656 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649763 [patent_doc_number] => 20200087411 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => TARGETED CHIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/483114 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14883575 [patent_doc_number] => 10421814 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-24 [patent_title] => Antibodies [patent_app_type] => utility [patent_app_number] => 15/883130 [patent_app_country] => US [patent_app_date] => 2018-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 36 [patent_no_of_words] => 25323 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15883130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12808681 [patent_doc_number] => 20180161397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => METHODS FOR MODULATING AN INFLAMMATORY RESPONSE [patent_app_type] => utility [patent_app_number] => 15/883879 [patent_app_country] => US [patent_app_date] => 2018-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15883879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311401 [patent_doc_number] => 20180207237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => IL-12 FORMULATIONS FOR ENHANCING HEMATOPOIESIS [patent_app_type] => utility [patent_app_number] => 15/881064 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15881064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357337 [patent_doc_number] => 20180230208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => TREATMENT FOR RHEUMATOID ARTHRITIS [patent_app_type] => utility [patent_app_number] => 15/880726 [patent_app_country] => US [patent_app_date] => 2018-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15880726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453038 [patent_doc_number] => 11267883 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Antibodies that specifically bind to human IL-15 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/471616 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 62 [patent_no_of_words] => 26291 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16471616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17074907 [patent_doc_number] => 11111292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Anti-IL-5 antibodies [patent_app_type] => utility [patent_app_number] => 15/848090 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 24 [patent_no_of_words] => 26894 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15848090 [rel_patent_id] =>[rel_patent_doc_number] =>)